Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.
2.

Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer.

Matsubara N, Yamada Y, Tabata KI, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H, Yano A, Kawakami S, Otsuka M, Fukasawa S.

Clin Genitourin Cancer. 2017 Dec;15(6):e1073-e1080. doi: 10.1016/j.clgc.2017.07.016. Epub 2017 Jul 26.

PMID:
28826931
3.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
4.

Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan.

Miyake H, Sugiyama T, Aki R, Matsushita Y, Tamura K, Motoyama D, Ito T, Otsuka A.

Clin Genitourin Cancer. 2018 Jun;16(3):219-225. doi: 10.1016/j.clgc.2017.11.007. Epub 2017 Dec 6.

PMID:
29274813
5.

Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting.

Oh WK, Cheng WY, Miao R, Vekeman F, Gauthier-Loiselle M, Duh MS, Drea E, Szatrowski TP.

Urol Oncol. 2018 Nov;36(11):500.e1-500.e9. doi: 10.1016/j.urolonc.2018.08.002. Epub 2018 Sep 7.

6.

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.

Lavaud P, Gravis G, Foulon S, Joly F, Oudard S, Priou F, Latorzeff I, Mourey L, Soulié M, Delva R, Krakowski I, Laguerre B, Théodore C, Ferrero JM, Beuzeboc P, Habibian M, Rolland F, Deplanque G, Pouessel D, Zanetta S, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Tubiana-Mathieu N, Machiels JP, Kouri CE, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Culine S, Boher JM, Tergemina-Clain G, Legoupil C, Fizazi K.

Eur Urol. 2018 May;73(5):696-703. doi: 10.1016/j.eururo.2017.09.022. Epub 2017 Oct 23.

PMID:
29074061
7.

Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer.

Francini E, Yip S, Ahmed S, Li H, Ardolino L, Evan CP, Kaymakcalan M, Shaw GK, Kantoff PW, Taplin ME, Alimohamed NS, Joshua AM, Heng DYC, Sweeney CJ.

Clin Genitourin Cancer. 2018 Apr;16(2):130-134. doi: 10.1016/j.clgc.2017.12.012. Epub 2017 Dec 27.

8.

Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.

Barata P, Emamekhoo H, Mendiratta P, Koshkin V, Tyler A, Ornstein M, Rini BI, Gilligan T, Kyriakopoulos C, Garcia JA.

Prostate. 2018 Sep;78(13):1035-1041. doi: 10.1002/pros.23663. Epub 2018 Jun 7.

PMID:
29882332
9.

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.

Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N.

Eur Urol. 2017 Apr;71(4):630-642. doi: 10.1016/j.eururo.2016.08.002. Epub 2016 Aug 31.

PMID:
27591931
10.

[AR-V7 Androgen Receptor Variant as a Predictor of Response to Androgen-receptor Targeting Agents Used to Treat Castration-refractory Metastatic Prostate Cancer].

Büchler T, Bobek V, Kološtová K.

Klin Onkol. Winter 2017;31(1):9-14. doi: 10.14735/amko20189. Review. Czech.

PMID:
29488772
11.

Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide.

Kumano Y, Hasegawa Y, Kawahara T, Yasui M, Miyoshi Y, Matsubara N, Uemura H.

Biomed Res Int. 2019 Jan 20;2019:9450838. doi: 10.1155/2019/9450838. eCollection 2019.

12.

Comparative Assessment of Efficacies Between 2 Alternative Therapeutic Sequences With Novel Androgen Receptor-Axis-Targeted Agents in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.

Miyake H, Hara T, Tamura K, Sugiyama T, Furuse H, Ozono S, Fujisawa M.

Clin Genitourin Cancer. 2017 Aug;15(4):e591-e597. doi: 10.1016/j.clgc.2016.12.015. Epub 2016 Dec 22.

PMID:
28063845
13.

Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.

Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP.

J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Epub 2015 Jul 18. Review.

PMID:
26196735
14.

Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer.

Jang HS, Koo KC, Cho KS, Chung BH.

Yonsei Med J. 2016 Sep;57(5):1070-8. doi: 10.3349/ymj.2016.57.5.1070.

15.
16.

Sequencing Treatment for Castration-Resistant Prostate Cancer.

Handy CE, Antonarakis ES.

Curr Treat Options Oncol. 2016 Dec;17(12):64. Review.

PMID:
27822685
17.

Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy.

Gartrell BA, Saad F.

Ther Adv Urol. 2015 Aug;7(4):194-202. doi: 10.1177/1756287215592288. Review.

18.

Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer.

Sathianathen NJ, Philippou YA, Kuntz GM, Konety BR, Gupta S, Lamb AD, Dahm P.

Cochrane Database Syst Rev. 2018 Oct 15;10:CD012816. doi: 10.1002/14651858.CD012816.pub2.

PMID:
30320443
19.

Castration-resistant prostate cancer: from new pathophysiology to new treatment.

Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, Sartor O, Saad F.

Eur Urol. 2014 Feb;65(2):289-99. doi: 10.1016/j.eururo.2013.08.008. Epub 2013 Aug 11. Review.

PMID:
23957948
20.

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.

Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y.

Eur Urol. 2015 Aug;68(2):228-35. doi: 10.1016/j.eururo.2014.04.015. Epub 2014 May 2.

PMID:
24837187

Supplemental Content

Support Center